Entry - #614867 - PEROXISOME BIOGENESIS DISORDER 5B; PBD5B - OMIM
# 614867

PEROXISOME BIOGENESIS DISORDER 5B; PBD5B


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
8q21.13 Peroxisome biogenesis disorder 5B 614867 AR 3 PEX2 170993
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal recessive
HEAD & NECK
Ears
- Hypoacusia (1 patient)
Eyes
- Slow saccades
- Oculomotor apraxia
- Nystagmus
- Retinitis pigmentosa (1 patient)
SKELETAL
Feet
- Pes cavus (1 patient)
MUSCLE, SOFT TISSUES
- Hypotonia
NEUROLOGIC
Central Nervous System
- Delayed development (in some patients)
- Cerebellar ataxia
- Unsteady gait
- Difficulty running
- Tremor
- Dysmetria
- Dysarthria
- Cerebellar atrophy
Peripheral Nervous System
- Hyporeflexia
- Axonal sensorimotor neuropathy (1 patient)
LABORATORY ABNORMALITIES
- Very long-chain fatty acids may be normal or increased
- Increased phytanic acid
- Increased pristanic acid
- Increased bile acid intermediates (DHCA and THCA)
MISCELLANEOUS
- Onset in infancy or childhood
- Variable severity
- Slowly progressive
- Six patients from 4 families have been reported (last curated January 2015)
MOLECULAR BASIS
- Caused by mutation in the peroxisome biogenesis factor 2 gene (PEX2, 170993.0002)
Peroxisome biogenesis disorder - PS214100 - 27 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.32 Peroxisome biogenesis disorder 6B AR 3 614871 PEX10 602859
1p36.32 Peroxisome biogenesis disorder 6A (Zellweger) AR 3 614870 PEX10 602859
1p36.22 Peroxisome biogenesis disorder 13A (Zellweger) AR 3 614887 PEX14 601791
1q21.1 Peroxisome biogenesis disorder 14B AR 3 614920 PEX11B 603867
1q23.2 Peroxisome biogenesis disorder 12A (Zellweger) AR 3 614886 PEX19 600279
2p15 Peroxisome biogenesis disorder 11A (Zellweger) AR 3 614883 PEX13 601789
2p15 Peroxisome biogenesis disorder 11B AR 3 614885 PEX13 601789
6p21.1 Peroxisome biogenesis disorder 4B AD, AR 3 614863 PEX6 601498
6p21.1 Peroxisome biogenesis disorder 4A (Zellweger) AR 3 614862 PEX6 601498
6p21.1 Heimler syndrome 2 AR 3 616617 PEX6 601498
6q23.3 Peroxisome biogenesis disorder 9B AR 3 614879 PEX7 601757
6q23.3 Rhizomelic chondrodysplasia punctata, type 1 AR 3 215100 PEX7 601757
6q24.2 Peroxisome biogenesis disorder 10A (Zellweger) AR 3 614882 PEX3 603164
6q24.2 ?Peroxisome biogenesis disorder 10B AR 3 617370 PEX3 603164
7q21.2 Peroxisome biogenesis disorder 1B (NALD/IRD) AR 3 601539 PEX1 602136
7q21.2 Peroxisome biogenesis disorder 1A (Zellweger) AR 3 214100 PEX1 602136
7q21.2 Heimler syndrome 1 AR 3 234580 PEX1 602136
8q21.13 Peroxisome biogenesis disorder 5B AR 3 614867 PEX2 170993
8q21.13 Peroxisome biogenesis disorder 5A (Zellweger) AR 3 614866 PEX2 170993
11p11.2 Peroxisome biogenesis disorder 8B AR 3 614877 PEX16 603360
11p11.2 Peroxisome biogenesis disorder 8A (Zellweger) AR 3 614876 PEX16 603360
12p13.31 Peroxisome biogenesis disorder 2A (Zellweger) AR 3 214110 PEX5 600414
12p13.31 Peroxisome biogenesis disorder 2B AR 3 202370 PEX5 600414
17q12 Peroxisome biogenesis disorder 3B AR 3 266510 PEX12 601758
17q12 Peroxisome biogenesis disorder 3A (Zellweger) AR 3 614859 PEX12 601758
22q11.21 Peroxisome biogenesis disorder 7B AR 3 614873 PEX26 608666
22q11.21 Peroxisome biogenesis disorder 7A (Zellweger) AR 3 614872 PEX26 608666

TEXT

A number sign (#) is used with this entry because of evidence that this form of peroxisome biogenesis disorder (PBD5B) is caused by homozygous or compound heterozygous mutation in the PEX2 gene (170993) on chromosome 8q21. Mutations in the PEX2 gene also cause the more severe disorder Zellweger syndrome (PBD5A; 614866).


Description

The overlapping phenotypes of neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD) represent the milder manifestations of the Zellweger syndrome spectrum (ZSS) of peroxisome biogenesis disorders. The clinical course of patients with the NALD and IRD presentation is variable and may include developmental delay, hypotonia, liver dysfunction, sensorineural hearing loss, retinal dystrophy, and visual impairment. Children with the NALD presentation may reach their teens, and those with the IRD presentation may reach adulthood (summary by Waterham and Ebberink, 2012).

For a complete phenotypic description and a discussion of genetic heterogeneity of PBD(NALD/IRD), see 601539.

Individuals with mutations in the PEX2 gene have cells of complementation group 5 (CG5, equivalent to CG10 and CGF). For information on the history of PBD complementation groups, see 214100.


Clinical Features

Shimozawa et al. (1999) studied a Welsh female with IRD who presented at the age of 1 year with delayed milestones and joint laxity. Later, retinitis pigmentosa manifested and biochemical investigation showed accumulation of very long chain fatty acids (VLCFAs) and phytanic acid and an abnormal bile acid profile. The activities of dihydroxyacetone phosphate acyltransferase (DHAP-AT) were reduced in platelets and fibroblasts. The patient died at 3 years of age following an episode of bronchiolitis.

Mandel et al. (1994) reported 2 brothers, aged 5 and 9 years, with neurodegenerative symptoms after the first year of life. They were born to consanguineous Israeli Arab parents. Both sibs were found to have elevated levels of plasma very long chain fatty acids, pipecolic and phytanic acids, and abnormal bile acid intermediates, suggesting a generalized peroxisome deficiency disorder. Peroxisomes were absent in 90% of hepatocytes, but normal peroxisomal functions were found in fibroblasts. Gootjes et al. (2004) reported further on the older brother. His development was described as normal in infancy, but by the age of 22 months, he had hypotonia, could not walk unassisted, and had cerebellar and vermian atrophy on MRI. The patient continued to deteriorate and died from pneumonia at age 13.

Sevin et al. (2011) reported 2 brothers, born of unrelated parents, who developed isolated progressive cerebellar ataxia at ages 3.5 and 18 years, respectively. The younger brother developed mild dysarthria at age 2.5 years and gait disturbances at age 3.5 years. He had a broad-based gait, but was able to run and climb stairs at age 7. The symptoms worsened at age 9: he was unable to run, had difficulty writing, and showed tremor, nystagmus, slow saccades, and hyporeflexia. Cognition was reported as normal. The older brother developed cerebellar signs with ataxia, dysmetria, dysarthria, hyporeflexia, and slow saccades with oculomotor apraxia at age 18 years. Brain imaging in both patients showed cerebellar atrophy. Laboratory studies showed increased phytanic and pristanic acid and moderately increased bile acid intermediates (DHCA and THCA). Very long-chain fatty acids were near normal, and pipecolic acid and plasmalogen synthesis were normal. These findings were consistent with a mild peroxisomal disorder.

Mignarri et al. (2012) reported a 51-year-old Italian man with a mild form of PBD5B, who had experienced childhood onset of slowly progressive cerebellar ataxia characterized by increased falls and unsteady walking at age 3 years. Clinical features as an adult included gait ataxia, gaze-evoked nystagmus, hypoacusis, dysarthria, dysmetria, areflexia, and pes cavus. Electrophysiologic studies showed a severe axonal sensorimotor polyneuropathy. Cognition was intact. Brain imaging showed cerebellar and pontine atrophy without signal abnormalities. Laboratory studies showed increased very long chain fatty acids, increased pristanic and phytanic acid, and increased bile acid intermediates, consistent with a mild peroxisomal defect.


Inheritance

The transmission pattern of PBD5B in the families reported by Sevin et al. (2011) was consistent with autosomal recessive inheritance.


Molecular Genetics

In a Welsh patient with IRD, Shimozawa et al. (1999) detected compound heterozygosity for a missense mutation (E55K; 170993.0002) and a nonsense mutation (R118X; 170993.0001) in the PEX2 gene.

In 1 of the sibs reported by Mandel et al. (1994) with a peroxisomal disorder, Gootjes et al. (2004) identified a homozygous mutation in the PEX2 gene (W223X; 170993.0005).

In 2 brothers with isolated cerebellar ataxia and biochemical evidence of a mild peroxisomal disorder, Sevin et al. (2011) identified a homozygous truncating mutation in the PEX2 gene (c.865_866insA; 170993.0006). Patient fibroblasts showed normal peroxisomes and contained catalase, suggesting that the mutant protein is localized correctly in the peroxisomal membrane and retains some activity. Further functional studies were not performed. The report expanded the phenotypic spectrum associated with PEX2 mutations to include mild and isolated autosomal recessive cerebellar ataxia.

In a 51-year-old Italian man, born of unrelated parents, with PBD5B manifest as childhood-onset cerebellar ataxia and an axonal sensorimotor polyneuropathy, Mignarri et al. (2012) identified compound heterozygosity for 2 previously identified mutations in patients with PBD5B (170993.0001 and 170993.0006). Patient fibroblasts showed mosaicism for a peroxisomal defect.


REFERENCES

  1. Gootjes, J., Elpeleg, O., Eyskens, F., Mandel, H., Mitanchez, D., Shimozawa, N., Suzuki, Y., Waterham, H. R., Wanders, R. J. A. Novel mutations in the PEX2 gene of four unrelated patients with a peroxisome biogenesis disorder. Pediat. Res. 55: 431-436, 2004. [PubMed: 14630978, related citations] [Full Text]

  2. Mandel, H., Espeel, M., Roels, F., Sofer, N., Luder, A., Iancu, T. C., Aizin, A., Berant, M., Wanders, R. J. A., Schutgens, R. B. H. A new type of peroxisomal disorder with variable expression in liver and fibroblasts. J. Pediat. 125: 549-555, 1994. [PubMed: 7931872, related citations] [Full Text]

  3. Mignarri, A., Vinciguerra, C., Giorgio, A., Ferdinandusse, S., Waterham, H., Wanders, R., Bertini, E., Dotti, M. T., Federico, A. Zellweger spectrum disorder with mild phenotype caused by PEX2 gene mutations. JIMD Rep. 6: 43-46, 2012. [PubMed: 23430938, related citations] [Full Text]

  4. Sevin, C., Ferdinandusse, S., Waterham, H. R., Wanders, R. J., Aubourg, P. Autosomal recessive cerebellar ataxia caused by mutations in the PEX2 gene. Orphanet J. Rare Dis. 6: 8, 2011. Note: Electronic Article. [PubMed: 21392394, related citations] [Full Text]

  5. Shimozawa, N., Imamura, A., Zhang, Z., Suzuki, Y., Orii, T., Tsukamoto, T., Osumi, T., Fujiki, Y., Wanders, R. J. A., Besley, G., Kondo, N. Defective PEX gene products correlate with the protein import, biochemical abnormalities, and phenotypic heterogeneity in peroxisome biogenesis disorders. J. Med. Genet. 36: 779-781, 1999. [PubMed: 10528859, related citations] [Full Text]

  6. Waterham, H. R., Ebberink, M. S. Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim. Biophys. Acta 1822: 1430-1441, 2012. [PubMed: 22871920, related citations] [Full Text]


Cassandra L. Kniffin - updated : 1/2/2015
Ingrid M. Wentzensen - updated : 7/8/2014
Creation Date:
Anne M. Stumpf : 10/12/2012
carol : 03/13/2018
carol : 06/29/2015
carol : 1/16/2015
mcolton : 1/7/2015
ckniffin : 1/2/2015
carol : 9/4/2014
carol : 7/8/2014
alopez : 10/26/2012
alopez : 10/25/2012
alopez : 10/24/2012

# 614867

PEROXISOME BIOGENESIS DISORDER 5B; PBD5B


ORPHA: 44, 772, 79189;   DO: 0081434;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
8q21.13 Peroxisome biogenesis disorder 5B 614867 Autosomal recessive 3 PEX2 170993

TEXT

A number sign (#) is used with this entry because of evidence that this form of peroxisome biogenesis disorder (PBD5B) is caused by homozygous or compound heterozygous mutation in the PEX2 gene (170993) on chromosome 8q21. Mutations in the PEX2 gene also cause the more severe disorder Zellweger syndrome (PBD5A; 614866).


Description

The overlapping phenotypes of neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD) represent the milder manifestations of the Zellweger syndrome spectrum (ZSS) of peroxisome biogenesis disorders. The clinical course of patients with the NALD and IRD presentation is variable and may include developmental delay, hypotonia, liver dysfunction, sensorineural hearing loss, retinal dystrophy, and visual impairment. Children with the NALD presentation may reach their teens, and those with the IRD presentation may reach adulthood (summary by Waterham and Ebberink, 2012).

For a complete phenotypic description and a discussion of genetic heterogeneity of PBD(NALD/IRD), see 601539.

Individuals with mutations in the PEX2 gene have cells of complementation group 5 (CG5, equivalent to CG10 and CGF). For information on the history of PBD complementation groups, see 214100.


Clinical Features

Shimozawa et al. (1999) studied a Welsh female with IRD who presented at the age of 1 year with delayed milestones and joint laxity. Later, retinitis pigmentosa manifested and biochemical investigation showed accumulation of very long chain fatty acids (VLCFAs) and phytanic acid and an abnormal bile acid profile. The activities of dihydroxyacetone phosphate acyltransferase (DHAP-AT) were reduced in platelets and fibroblasts. The patient died at 3 years of age following an episode of bronchiolitis.

Mandel et al. (1994) reported 2 brothers, aged 5 and 9 years, with neurodegenerative symptoms after the first year of life. They were born to consanguineous Israeli Arab parents. Both sibs were found to have elevated levels of plasma very long chain fatty acids, pipecolic and phytanic acids, and abnormal bile acid intermediates, suggesting a generalized peroxisome deficiency disorder. Peroxisomes were absent in 90% of hepatocytes, but normal peroxisomal functions were found in fibroblasts. Gootjes et al. (2004) reported further on the older brother. His development was described as normal in infancy, but by the age of 22 months, he had hypotonia, could not walk unassisted, and had cerebellar and vermian atrophy on MRI. The patient continued to deteriorate and died from pneumonia at age 13.

Sevin et al. (2011) reported 2 brothers, born of unrelated parents, who developed isolated progressive cerebellar ataxia at ages 3.5 and 18 years, respectively. The younger brother developed mild dysarthria at age 2.5 years and gait disturbances at age 3.5 years. He had a broad-based gait, but was able to run and climb stairs at age 7. The symptoms worsened at age 9: he was unable to run, had difficulty writing, and showed tremor, nystagmus, slow saccades, and hyporeflexia. Cognition was reported as normal. The older brother developed cerebellar signs with ataxia, dysmetria, dysarthria, hyporeflexia, and slow saccades with oculomotor apraxia at age 18 years. Brain imaging in both patients showed cerebellar atrophy. Laboratory studies showed increased phytanic and pristanic acid and moderately increased bile acid intermediates (DHCA and THCA). Very long-chain fatty acids were near normal, and pipecolic acid and plasmalogen synthesis were normal. These findings were consistent with a mild peroxisomal disorder.

Mignarri et al. (2012) reported a 51-year-old Italian man with a mild form of PBD5B, who had experienced childhood onset of slowly progressive cerebellar ataxia characterized by increased falls and unsteady walking at age 3 years. Clinical features as an adult included gait ataxia, gaze-evoked nystagmus, hypoacusis, dysarthria, dysmetria, areflexia, and pes cavus. Electrophysiologic studies showed a severe axonal sensorimotor polyneuropathy. Cognition was intact. Brain imaging showed cerebellar and pontine atrophy without signal abnormalities. Laboratory studies showed increased very long chain fatty acids, increased pristanic and phytanic acid, and increased bile acid intermediates, consistent with a mild peroxisomal defect.


Inheritance

The transmission pattern of PBD5B in the families reported by Sevin et al. (2011) was consistent with autosomal recessive inheritance.


Molecular Genetics

In a Welsh patient with IRD, Shimozawa et al. (1999) detected compound heterozygosity for a missense mutation (E55K; 170993.0002) and a nonsense mutation (R118X; 170993.0001) in the PEX2 gene.

In 1 of the sibs reported by Mandel et al. (1994) with a peroxisomal disorder, Gootjes et al. (2004) identified a homozygous mutation in the PEX2 gene (W223X; 170993.0005).

In 2 brothers with isolated cerebellar ataxia and biochemical evidence of a mild peroxisomal disorder, Sevin et al. (2011) identified a homozygous truncating mutation in the PEX2 gene (c.865_866insA; 170993.0006). Patient fibroblasts showed normal peroxisomes and contained catalase, suggesting that the mutant protein is localized correctly in the peroxisomal membrane and retains some activity. Further functional studies were not performed. The report expanded the phenotypic spectrum associated with PEX2 mutations to include mild and isolated autosomal recessive cerebellar ataxia.

In a 51-year-old Italian man, born of unrelated parents, with PBD5B manifest as childhood-onset cerebellar ataxia and an axonal sensorimotor polyneuropathy, Mignarri et al. (2012) identified compound heterozygosity for 2 previously identified mutations in patients with PBD5B (170993.0001 and 170993.0006). Patient fibroblasts showed mosaicism for a peroxisomal defect.


REFERENCES

  1. Gootjes, J., Elpeleg, O., Eyskens, F., Mandel, H., Mitanchez, D., Shimozawa, N., Suzuki, Y., Waterham, H. R., Wanders, R. J. A. Novel mutations in the PEX2 gene of four unrelated patients with a peroxisome biogenesis disorder. Pediat. Res. 55: 431-436, 2004. [PubMed: 14630978] [Full Text: https://doi.org/10.1203/01.PDR.0000106862.83469.8D]

  2. Mandel, H., Espeel, M., Roels, F., Sofer, N., Luder, A., Iancu, T. C., Aizin, A., Berant, M., Wanders, R. J. A., Schutgens, R. B. H. A new type of peroxisomal disorder with variable expression in liver and fibroblasts. J. Pediat. 125: 549-555, 1994. [PubMed: 7931872] [Full Text: https://doi.org/10.1016/s0022-3476(94)70006-0]

  3. Mignarri, A., Vinciguerra, C., Giorgio, A., Ferdinandusse, S., Waterham, H., Wanders, R., Bertini, E., Dotti, M. T., Federico, A. Zellweger spectrum disorder with mild phenotype caused by PEX2 gene mutations. JIMD Rep. 6: 43-46, 2012. [PubMed: 23430938] [Full Text: https://doi.org/10.1007/8904_2011_102]

  4. Sevin, C., Ferdinandusse, S., Waterham, H. R., Wanders, R. J., Aubourg, P. Autosomal recessive cerebellar ataxia caused by mutations in the PEX2 gene. Orphanet J. Rare Dis. 6: 8, 2011. Note: Electronic Article. [PubMed: 21392394] [Full Text: https://doi.org/10.1186/1750-1172-6-8]

  5. Shimozawa, N., Imamura, A., Zhang, Z., Suzuki, Y., Orii, T., Tsukamoto, T., Osumi, T., Fujiki, Y., Wanders, R. J. A., Besley, G., Kondo, N. Defective PEX gene products correlate with the protein import, biochemical abnormalities, and phenotypic heterogeneity in peroxisome biogenesis disorders. J. Med. Genet. 36: 779-781, 1999. [PubMed: 10528859] [Full Text: https://doi.org/10.1136/jmg.36.10.779]

  6. Waterham, H. R., Ebberink, M. S. Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim. Biophys. Acta 1822: 1430-1441, 2012. [PubMed: 22871920] [Full Text: https://doi.org/10.1016/j.bbadis.2012.04.006]


Contributors:
Cassandra L. Kniffin - updated : 1/2/2015
Ingrid M. Wentzensen - updated : 7/8/2014

Creation Date:
Anne M. Stumpf : 10/12/2012

Edit History:
carol : 03/13/2018
carol : 06/29/2015
carol : 1/16/2015
mcolton : 1/7/2015
ckniffin : 1/2/2015
carol : 9/4/2014
carol : 7/8/2014
alopez : 10/26/2012
alopez : 10/25/2012
alopez : 10/24/2012